Q-omics provides the consensus-scored KRBA2 profile across patient tissues and cancer cell-line models. KRBA2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRBA2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, KRBA2 RNA expression shows 20,182 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where KRBA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRBA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRBA2 survival associations across molecular data types. KRBA2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRBA2 RNA expression–survival associations across cancer types. High KRBA2 expression shows unfavorable associations in LUSC, but favorable associations in KIRC, HNSC, UCS, PAAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRBA2 RNA expression.
This table summarizes KRBA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRBA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRBA2 shows lower tumor expression in KIRC, THCA, BRCA, KICH, UCEC and HNSC. The KIRC box plot shows higher KRBA2 RNA expression in normal versus tumor tissue (log2 FC = −0.516, t-test p < 0.001).
This table shows molecular features associated with KRBA2 in patient tissues and cancer cell lines. In patient samples, KRBA2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KRBA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
